The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
Arista Networks Beats Expectations and Provides Fresh Support for the AI Investment Cycle
Market wrap (05.08.2026)
AMD Did Everything Right… But Only Right
SpaceX Shares Drop 6% After Earnings 🚩 Is Space No Longer Enough for Wall Street?